FLOT alone

Phase 3Small molecule

AstraZeneca

FLOT alone is one of 57 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaRecruiting

Gastroesophageal AdenocarcinomaRecruiting

Gastroesophageal Junction CancerActive, not recruiting

Gastric AdenocarcinomaPhase 1

Recruiting

Gastroesophageal AdenocarcinomaPhase 2

Recruiting

Gastroesophageal Junction CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Gastric Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

16 2

Koselugo

Gleevec

Tukysa

Tegretol

Taxol

14 7

Keytruda

Merck & Co.

Phase 3

5 8

Opdivo

Bristol-Myers Squibb

Phase 3

3 9

Elunate

Takeda

Phase 3

1 10

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Gastric Adenocarcinoma

NCT07059299

Phase 3Active, not recruiting

Gastroesophageal Junction Cancer

NCT04592913

Q3 2029

Phase 2Recruiting

Gastroesophageal Adenocarcinoma

NCT07069712

Clinical

Trials by Indication[1]

Gastric1 trial

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2/3·NCT02581462·81 enrolled

Gastric Cancer1 trial

Dragon III: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer

Completed·RRuijin Hospital·Phase 2·NCT03636893·74 enrolled

Gastroesophageal Junction Cancer1 trial

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT04592913·957 enrolled

Gastric Adenocarcinoma1 trial

A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma

Recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 1·NCT07059299·18 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (GEMINI-PeriOp GC)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07069712·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for FLOT alone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FLOT alone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FLOT alone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

FLOT alone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2029

Trials by Indication[1]

Gastric1 trial

Gastric Cancer1 trial

Gastroesophageal Junction Cancer1 trial

Gastric Adenocarcinoma1 trial

Gastroesophageal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News